Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 2/2008

01.02.2008 | Review Article

Pathological Gambling

An Update on Neuropathophysiology and Pharmacotherapy

verfasst von: Iulian Iancu, Katherine Lowengrub, Yael Dembinsky, Moshe Kotler, Dr Pinhas N. Dannon

Erschienen in: CNS Drugs | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Neurobiological research has shown the potential involvement of serotonergic, dopaminergic and opioid dysfunction in the pathophysiology of pathological gambling. In this review, we present current theories of the neuropathology of pathological gambling, paying particular attention to the role of the neural circuitry underlying motivation, reward, decision-making and impulsivity. This review also presents a literature review of current pharmacological treatment strategies for pathological gambling, such as SSRIs, opioid receptor antagonists, anti-addiction drugs and mood stabilizers, and also discusses the role of nonpharmacological interventions.
A hypothetical model of the clinical subtypes of pathological gambling is presented, e.g. the impulsive subtype, the obsessive-compulsive subtype and the addictive subtype. This model attempts to integrate current knowledge in the field of pathological gambling regarding neuropathology, psychiatric co-morbidity, family history, genetics, course of illness, gender and response to pharmacological treatment. Finally, it is proposed that the existence of possible clinical subtypes of pathological gambling may provide a potential framework for matching the various subtypes with specific pharmacotherapies.
Literatur
1.
Petry NM, Armentano C. Prevalence, assessment, and treatment of pathological gambling: a review. Psychiatr Serv 1999; 50(8): 1021–7PubMed
2.
Shaffer HJ, Hall MN, Van der Bilt J. Estimating the prevalence of disorder gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 1999; 89: 1369–76PubMedCrossRef
3.
Hollander E, Buchalter AJ, DeCaria CM. Pathological gambling. Psychiatr Clin North Am 2000; 23(3): 629–42PubMedCrossRef
4.
Dell’Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of pathological gambling: a critical review. Clin Pract Epidemol Ment Health 2005; 1: 21CrossRef
5.
Dell’Osso B, Hollander E. The impact of comorbidity on the management of pathological gambling. CNS Spectr 2005; 10(8): 619–21PubMed
6.
Ibanez A, Blanco C, Donahue E, et al. Psychiatric comorbidity in pathological gamblers seeking treatment. Am J Psychiatry 2001; 158(10): 1733–5PubMedCrossRef
7.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association Inc., 1994
8.
The ICD-10 classification of mental and behavioral disorders. Geneva: World Health Organization, 1992
9.
Shah KR, Eisen SA, Xian H, et al. Genetic studies of pathological gambling: a review of methodology and analyses of data from the Vietnam era twin registry. J Gambl Stud 2005; 21(2): 179–203PubMedCrossRef
10.
Black DW, Monahan PO, Temkit M, et al. A family study of pathological gambling. Psychiatry Res 2006; 141(3): 295–303PubMedCrossRef
11.
Steel Z, Blaszczynski A. Impulsivity, personality disorders and pathological gambling severity. Addiction 1998; 93(6): 895–905PubMedCrossRef
12.
Scherrer JF, Xian H, Shah KR, et al. Effect of genes, environment, and lifetime co-occurring disorders on health-related quality of life in problem and pathological gamblers. Arch Gen Psychiatry 2005; 62(6): 677–83PubMedCrossRef
13.
Hollander E. Treatment of obsessive-compulsive spectrum disorders with SSRIs. Br J Psychiatry Suppl 1998; 35: 7–12PubMed
14.
Blaszczynski A. Pathological gambling and obsessive-compulsive spectrum disorders. Psychol Rep 1999; 84: 107–13PubMedCrossRef
15.
Frost RO, Meagher BM, Riskind JH. Obsessive-compulsive features in pathological lottery and scratch-ticket gamblers. J Gambl Stud 2001; 17(1): 5–19PubMedCrossRef
16.
Tamminga CA, Nestler EJ. Pathological gambling: focusing on the addiction, not the activity. Am J Psychiatry 2006; 163(2): 180–1PubMedCrossRef
17.
Petry NM. Should thescope of addictive behaviors be broadened to include pathological gambling? Addiction 2006; 101Suppl. 1: 152–60PubMedCrossRef
18.
Nutt DJ. Addiction: brain mechanisms and their treatment implications. Lancet 1996; 347(8993): 31–6PubMedCrossRef
19.
Spinella M. Evolutionary mismatch, neural reward circuits, and pathological gambling. Int J Neurosci 2003; 113(4): 503–12PubMedCrossRef
20.
Volkow ND, Fowler JS, Wang GJ. Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002; 13(5–6): 355–66PubMedCrossRef
21.
Reuter J, Raedler T, Rose M, et al. Pathological gambling is linked to reduced activation of the mesolimbic reward system. Nat Neurosci 2005; 8(2): 147–8PubMedCrossRef
22.
Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005; 162(8): 1403–13PubMedCrossRef
23.
Chambers RA, Potenza MN. Neurodevelopment, impulsivity, and adolescent gambling. J Gambl Stud 2003; 19(1): 53–84PubMedCrossRef
24.
Berridge KC. The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology (Berl) 2007; 191(3): 391–431CrossRef
25.
Goldstein RZ, Volkow ND. Drug addiction and its underlying neurological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159(10): 1642–52PubMedCrossRef
26.
Jentsch JD, Taylor JR. Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl) 1999; 146(4): 373–90CrossRef
27.
Potenza MN, Steinberg MA, Skudlarski P, et al. Gambling urges in pathological gambling: a functional magnetic resonance imaging study. Arch Gen Psychiatry 2003; 60(8): 818–36CrossRef
28.
Bechara A. Neurobiology of decision-making: risk and reward. Semin Clin Neuropsychiatry 2001; 6(3): 205–16PubMedCrossRef
29.
Brand M, Kalbe E, Labudda K, et al. Decision-making impairments in patients with pathological gambling. Psychiatry Res 2005; 133: 91–9PubMedCrossRef
30.
Kertzman S, Lowengrub K, Aizer A, et al. Stroop performance in pathological gamblers. Psychiatry Res 2006; 142(1): 1–10PubMedCrossRef
31.
Potenza MN, Leung HC, Blumberg HP, et al. An FMRI Stroop task study of ventromedial prefrontal cortical function in pathological gamblers. Am J Psychiatry 2003; 160(11): 1990–4PubMedCrossRef
32.
Cavedini P, Riboldi G, Keller R, et al. Frontal lobe dysfunction in pathological gambling patients. Biol Psychiatry 2002; 51(4): 334–41PubMedCrossRef
33.
Soubrie P. Serotonergic neurons and behaviour [in French]. J Pharmacol 1986; 17(2): 107–12PubMed
34.
Zald DH, Boileau I, El-Dearedy W, et al. Dopamine transmission in the human striatum during monetary reward tasks. J Neurosci 2004; 24(17): 4105–12PubMedCrossRef
35.
Nordin C, Eklundh T. Altered CSF 5-HIAA disposition in pathological male gamblers. CNS Spectr 1999; 4: 25–33PubMed
36.
Carrasco JL, Saiz-Ruiz J, Hollander E, et al. Low platelet monoamine oxidase activity in pathological gambling. Acta Psychiatr Scand 1994; 90(6): 427–31PubMedCrossRef
37.
Moreno I, Saiz-Ruiz J, Lopez-Ibor JJ. Serotonin and gambling behavior. Hum Psychopharmacol 1991; 6: S9–12CrossRef
38.
DeCaria CM, Begaz T, Holander E. Serotonergic and noradrenergic function in pathological gambling. CNS Spectr 1998; 3: 38–47
39.
Roy A, DeJong J, Ferraro T, et al. CSF GABA and neuropeptides in pathological gamblers and normal controls. Psychiatry Res 1989; 30(2): 137–44PubMedCrossRef
40.
Grant JE, Kim SW, Potenza MN. Advances in the pharmacological treatment of pathological gambling. J Gambl Stud 2003; 19(1): 85–109PubMedCrossRef
41.
Di Chiara G. Drug addiction as dopamine-dependent associative learning disorder. Eur J Pharmacol 1999; 375(1–3): 13–30PubMedCrossRef
42.
Black KJ, Friedman JH. Repetitive and impulsive behaviors in treated Parkinson disease. Neurology 2006; 67(7): 1118–9PubMedCrossRef
43.
Grant JE, Williams KA, Kim SW. Update on pathological gambling. Curr Psychiatry Rep 2006; 8(1): 53–8PubMedCrossRef
44.
Koran LM, Bullock KD, Hartston HJ. Citalopram treatment of compulsive shopping: an open-label study. J Clin Psychiatry 2002; 63(8): 704–8PubMedCrossRef
45.
Hollander E, DeCaria CM, Finkell JN, et al. A randomized double-blind fluvoxamine/placebo crossover trial in pathologic gambling. Biol Psychiatry 2000; 47(9): 813–7PubMedCrossRef
46.
Blanco C, Petkova E, Ibanez A, et al. A pilot placebo-controlled study of fluvoxamine for pathological gambling. Ann Clin Psychiatry 2002; 14(1): 9–15PubMed
47.
Kim SW, Grant JE, Adson DE, et al. A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry 2002; 63(6): 501–7PubMedCrossRef
48.
Grant JE, Kim SW, Potenza MN, et al. Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial. Int Clin Psychopharmacol 2003; 18(4): 243–9PubMedCrossRef
49.
Saiz-Ruiz J, Blanco C, Ibanez A, et al. Sertraline treatment of pathological gambling: a pilot study. J Clin Psychiatry 2005; 66(1): 28–33PubMedCrossRef
50.
Grant JE, Potenza MN. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol 2006; 21(4): 203–9PubMedCrossRef
51.
Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 2002; 63(1): 44–8PubMedCrossRef
52.
Pallanti S, Baldini Rossi N, Sood E, et al. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry 2002; 63(11): 1034–9PubMedCrossRef
53.
Coccaro EF, Kavoussi RJ, Sheline YI, et al. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Arch Gen Psychiatry 1996; 53(6): 531–6PubMedCrossRef
54.
Hollister LE, Schwin RL, Kasper P. Naltrexone treatment of opiate-dependent persons. Drug Alcohol Depend 1977; 2(3): 203–9PubMedCrossRef
55.
Anton RF. Pharmacologic approaches to the management of alcoholism. J Clin Psychiatry 2001; 62Suppl. 20: 11–7PubMed
56.
Kim SW, Grant JE. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 2001; 16(5): 285–9PubMedCrossRef
57.
Kim SW, Grant JE, Adson DE, et al. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49(11): 914–21PubMedCrossRef
58.
Grant JE, Potenza MN, Hollander E, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163(2): 303–12PubMedCrossRef
59.
Zwar N, Richmond R. Bupropion sustained release: a therapeutic review of Zyban. Aus Fam Physician 2002; 31: 443–7
60.
Gelenberg AJ, Bassuk EL, editors. The practitioner’s guide to psychoactive drugs. 4th ed. New York: Plenum, 1997CrossRef
61.
Bechara A. Risky business: emotion, decision-making, and addiction. J Gambl Stud 2003; 19(1): 23–51PubMedCrossRef
62.
Tardieu S, Poirier Y, Micallef J, et al. Amphetamine-like stimulant cessation in an abusing patient treated with bupropion. Acta Psychiatr Scand 2004; 109(1): 75–7, discussion 77-8PubMedCrossRef
63.
Black D. An open-label trial of bupropion in the treatment of pathological gambling. J Clin Psychopharmacology 2004; 24(1): 108–9CrossRef
64.
Dannon PN, Lowengrub K, Musin E, et al. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. J Clin Psychopharmacol 2005; 25(6): 593–6PubMedCrossRef
65.
Dannon PN, Lowengrub K, Musin E, et al. Sustained release bupropion in the treatment of SSRI nonresponder pathological gamblers: pilot study and review of the literature. Therapy 2005; 2(5): 753–9CrossRef
66.
Pallanti S, Quercioli L, Sood E, et al. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002; 63(7): 559–65PubMedCrossRef
67.
Hollander E, Pallanti S, Allen A, et al. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 2005; 162(1): 137–45PubMedCrossRef
68.
Lyseng-Williamson KA, Yang LP. Topiramate: a review of its use in the treatment of epilepsy. Drugs 2007; 67(15): 2231–56PubMedCrossRef
69.
McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry 2003; 160(2): 255–61PubMedCrossRef
70.
Dannon PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol 2003; 26(1): 1–4PubMedCrossRef
71.
Dannon PN, Lowengrub K, Gonopolski Y, et al. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. Clin Neuropharmacol 2005; 28(1): 6–10PubMedCrossRef
72.
Sylvain C, Ladoucuer R, Boisvert JM. Cognitive and behavioral treatment of pathological gambling: a controlled study. J Consult Clin Psychol 1997; 65(5): 727–32PubMedCrossRef
73.
Echeburua E, Baez C, Fernandez-Montalvo J. Comparative effectiveness of three therapeutic modalities in the psychological treatment of pathological gambling. Behav Cogn Psychother 1996; 24: 51–72CrossRef
74.
Echeburua E, Fernandez-Montalvo J, Baez C. Prevention in the treatment of slot-machine pathological gambling: long-term outcome. Behavior Therapy 2000; 31: 351–64CrossRef
75.
Petry NM, Ammerman Y, Bohl J, et al. Cognitive-behavioral therapy for pathological gamblers. J Consult Clin Psychol 2006; 74(3): 555–67PubMedCrossRef
76.
McCusker CG. Cognitive biases and addiction: an evolution in theory and method. Addiction 2001; 96(1): 47–56PubMedCrossRef
77.
Toneatto T. Cognitive psychopathology of problem gambling. Subst Use Misuse 1999; 34(11): 1593–604PubMedCrossRef
78.
Ladouceur R, Sylvain C, Boutin C, et al. Group therapy for pathological gamblers: a cognitive approach. Behav Res Ther 2003; 41(5): 587–96PubMedCrossRef
79.
Toneatto T, Ladoceur R. Treatment of pathological gambling: a critical review of the literature. Psychol Addict Behav 2003; 17(4): 284–92PubMedCrossRef
80.
Kausch O, Rugle L, Rowland DY. Lifetime histories of trauma among pathological gamblers. Am J Addict 2006; 15(1): 35–43PubMedCrossRef
81.
Waska R. Addictions and the quest to control the object. Am J Psychoanal 2006; 66(1): 43–62PubMedCrossRef
82.
Goudriaan AE, Oosterlaan J, de Beurs E, et al. Neurocognitive functions in pathological gambling: a comparison with alcohol dependence, Tourette syndrome and normal controls. Addiction 2006; 101(4): 534–47PubMedCrossRef
83.
Ravindran AV, Telner J, Bhatla R, et al. Pathological gambling: treatment correlates. Eur Neuropsychopharmacol 2006; 16Suppl. 4: 20
84.
Dannon PN, Lowengrub K, Sasson M, et al. Comorbid psychiatric diagnoses in kleptomania and pathological gambling: a preliminary comparison study. Eur Psychiatry 2004; 19(5): 299–302PubMedCrossRef
85.
Dannon PN, Lowengrub K, Mester R, et al. Pathological gambling: comorbid psychiatric diagnoses in patients and their families. Israeli J Psychiatry 2006; 43(2): 88–92
86.
Dannon PN, Lowengrub K, Shagi B, et al. Dual psychiatric diagnoses and substance abuse in pathological gamblers: a preliminary gender comparison study. J Addict Disord 2006; 25(3): 49–54CrossRef
87.
Grant JE, Kim SW. Comorbidity of impulse control disorders in pathological gamblers. Acta Psychiatr Scand 2003; 108(3): 203–7PubMedCrossRef
88.
Lynch WJ, Maciejewski PK, Potenza MN. Psychiatric correlates of gambling in adolescents and young adults grouped by age at gambling onset. Arch Gen Psychiatry 2004; 61(11): 1116–22PubMedCrossRef
89.
Vachon J, Vitaro F, Wanner B, et al. Adolescent gambling: relationships with parent gambling and parenting practices. Psychol Addict Behav 2004; 18(4): 398–401PubMedCrossRef
90.
Kvale G, Holsten F. Outcome of pharmacological treatments of pathological gambling meta-analysis. J Clin Psychopharmacol 2007; 27(4): 357–64PubMedCrossRef
91.
Pettinati HM. The use of selective serotonin reuptake inhibitors in treating alcoholic subtypes. J Clin Psychiatry 2001; 62Suppl. 20: 26–31PubMed
92.
Blanco C, Hasin DS, Petry N, et al. Sex differences in subclinical and DSM-IV pathological gambling: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 2006; 36(7): 943–53PubMedCrossRef
93.
Desai RA, Maciejewski PK, Pantalon MV, et al. Gender differences in adolescent gambling. Ann Clin Psychiatry 2005; 17(4): 249–58PubMedCrossRef
94.
Hollander E, Wong CM. Obsessive-compulsive spectrum disorders. J Clin Psychiatry 1995; 56Suppl. 4: 3–6, discussion 53-5PubMed
95.
Thase ME. Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidence. CNS Spectr 2004; 9(11): 808–16, 818-21PubMed
96.
Potenza MN, Fiellin DA, Heninger GR, et al. Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med 2002; 17(9): 721–32PubMedCrossRef
97.
Petry NM. How treatments for pathological gambling can be informed by treatments for substance use disorders. Exp Clin Psychopharmacol 2002; 10(3): 184–92PubMedCrossRef
98.
Kim SW, Grant JE, Yoon G, et al. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. Clin Neuropharmacol 2006; 29(2): 77–9PubMedCrossRef
99.
Slutske WS. Natural recovery and treatment-seeking in pathological gambling: results of two US national surveys. Am J Psychiatry 2006; 163(2): 297–302PubMedCrossRef
100.
Weite JW, Wieczorek WF, Barnes GM, et al. The relationship of ecological and geographic factors to gambling behavior and pathology. J Gambl Stud 2004; 20(4): 405–10CrossRef
Metadaten
Titel
Pathological Gambling
An Update on Neuropathophysiology and Pharmacotherapy
verfasst von
Iulian Iancu
Katherine Lowengrub
Yael Dembinsky
Moshe Kotler
Dr Pinhas N. Dannon
Publikationsdatum
01.02.2008
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 2/2008
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200822020-00004

Weitere Artikel der Ausgabe 2/2008

CNS Drugs 2/2008 Zur Ausgabe

Adis Spotlight

Spotlight on Topiramate in Epilepsy

Current Opinion

Office-Based Maintenance Treatment of Opioid Dependence

Current Opinion

Treatment of Cognitive Impairment in Multiple Sclerosis

Original Research Article

Long-Acting Methylphenidate-OROS in Youths with Attention-Deficit Hyperactivity Disorder Suboptimally Controlled with Immediate-Release Methylphenidate

Leading Article

Secondary Stroke Prevention

Review Article

Antidepressants as Analgesics

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise